463 patents
Page 21 of 24
Utility
Bispecific Antigen-binding Molecule
10 Jun 20
Provided herein relates to antigen-binding molecules, in particular bispecific antigen-binding molecules that bind to a cancer cell antigen and an immune cell surface molecule.
John J. Rossi, Sarah Yoon, Piotr Marek Swiderski, Nagy Habib, John Ernest Shively
Filed: 9 Aug 18
Utility
Costimulatory chimeric antigen receptor T cells targeting IL13Rα2
8 Jun 20
Chimeric transmembrane immunoreceptors (CAR) which include an extracellular domain that includes IL-13 or a variant thereof that binds interleukin-13Rα2 (IL13Rα2), a transmembrane region, a costimulatory domain and an intracellular signaling domain are described.
Christine E. Brown, Stephen J. Forman
Filed: 11 Mar 18
Utility
Rna Aptamers Against Transferrin Receptor (TFR)
3 Jun 20
A ribonucleic acid compound is disclosed, the ribonucleic acid compound comprising, or consisting of, an RNA sequence having at least 90% sequence identity to SEQ ID NO: 1, wherein said RNA sequence has a length of 29 nucleotides or fewer, and wherein the RNA sequence is capable of binding to a transferrin receptor (TfR).
John J. Rossi, Sorah Yoon, Nagy Habib
Filed: 9 Aug 18
Utility
Microwave coaptive surgical sealing tool
1 Jun 20
A coaptive surgical sealing tool may be similar to an ordinary hemostat with long (50, 60, 70 or 80 mm) thin jaws for sliding into the liver parenchyma, without tearing the larger blood vessels.
Gagandeep Singh
Filed: 21 Jan 18
Utility
Design and Development of Masked Therapeutic Antibodies to Limit Off-target Effects
27 May 20
In one embodiment, a masked monoclonal antibody (mAb) is provided, the mAb, encoded by a nucleic acid sequence or an amino acid sequence molecule comprising a signal sequence, a masking epitope sequence, a linker sequence that is cleavable by a protease specific to a target tissue; and an antibody or a functional fragment thereof.
John C. Williams, Cindy Zer, Kendra N. Avery, Ulrich Rodeck, Joshua M. Donaldson, Csaba Kari
Filed: 1 Jul 19
Utility
CD123-specific chimeric antigen receptor redirected T cells and methods of their use
25 May 20
A family of chimeric antigen receptors (CARs) containing a CD123 specific scFv was developed to target different epitopes on CD123.
Stephen J. Forman, Armen Mardiros, Christine E. Brown, Uma Maheswara Rao Jonnalagadda
Filed: 21 May 17
Utility
Expression System for Expressing Herpesvirus Glycoprotein Complexes
20 May 20
Disclosed is an expression system for expressing a herpesvirus glycoprotein complex.
Felix WUSSOW, Don J. DIAMOND
Filed: 12 Jul 18
Utility
Meta-stable Oligonucleotides Junctions for Delivery of Therapeutics
20 May 20
Disclosed herein are multi-way oligonucleotide junctions for delivering one or more cargo molecules to a biological target and method of making such junctions.
Si-ping HAN, Marwa Ben HAJ SALAH, Lisa SCHERER, William A. GODDARD, III, John J. ROSSI
Filed: 13 Jul 18
Utility
MVA-gH/gL-PC VACCINE DERIVED ANTIBODIES NEUTRALIZING HUMAN CYTOMEGALOVIRUS INFECTIVITY AND METHODS THEREOF
20 May 20
Disclosed are vaccine-derived neutralizing antibodies (NAbs) for CMV infections and small peptides which define precise recognition elements of the antigens by the NAbs.
Don J. DIAMOND, Flavia CHIUPPESI, Felix WUSSOW
Filed: 10 Nov 19
Utility
Tumor Associated Vaccines and Compositions for Disrupting Tumor-derived Immunosuppression for Use In Combination Cancer Immunotherapy
20 May 20
In one embodiment, a single modality cancer immunotherapy regimen that includes a therapeutic composition is provided.
Don J. DIAMOND, Edwin MANUEL
Filed: 24 Nov 19
Utility
DNA2 Inhibitors for Cancer Treatment
13 May 20
Disclosed herein, inter alia, are compositions and methods for inhibiting DNA2.
Binghui Shen, Judith Campbell, Li Zheng, Hongzhi Li, David Horne, Jun Xie, Kenneth Karanja
Filed: 12 Jan 20
Utility
Methods and Compositions for Measuring Beta Cell Death
13 May 20
Provided herein are, inter alia, nucleic acids, methods, and kits for detecting unmethylated DNA in body fluid sample of a subject.
Kevin Ferreri, Mohamed I. Husseiny Elsayed
Filed: 7 Jul 19
Utility
Peptide inhibitors of twist
11 May 20
The disclosure provides, inter alia, compositions comprising TWIST peptide inhibitors and optionally one or more anti-cancer agents, and methods of using the compositions for the treatment of cancer.
Carlotta A. Glackin
Filed: 14 Nov 17
Utility
Methods, compositions, and kits for detection of aspergillosis
11 May 20
Provided herein are methods for detecting an Aspergillus protease in a sample, diagnosing a subject with aspergillosis caused by an Aspergillus infection based on the presence of an Aspergillus protease in a sample, and methods of aspergillosis treatment that incorporate these diagnostic methods.
Markus Kalkum, Karine Bagramyan, Diana Diaz-Arevalo, James I. Ito, Sanjeet Dadwal
Filed: 14 Aug 16
Utility
Detection and Treatment of Neurological Diseases
29 Apr 20
Disclosed are methods of detecting abnormal expression of one or more genes associated with a neurological disease such as the Alexander disease, the Alzheimer's disease, the Parkinson disease, the Huntington disease, multiple sclerosis, and amyotrophic lateral sclerosis.
Yanhong Shi, Li Li
Filed: 7 Jul 19
Utility
m6A mRNA MODIFICATION IN CANCER TREATMENT
29 Apr 20
Disclosed herein are methods of treating cancer by increasing mRNA m6A methylation level and/or decreasing mRNA m6A demethylation in cancer stem cells.
Yanhong SHI, Qi CUI
Filed: 12 Mar 18
Utility
Coaptive surgical sealing tool
27 Apr 20
A coaptive surgical sealing tool may be similar to an ordinary hemostat with long (50, 60, 70 or 80 mm) thin jaws for sliding into the liver parenchyma, without tearing the larger blood vessels.
Gagandeep Singh
Filed: 21 Dec 17
Utility
Programmable Thermoresponsive Gels
22 Apr 20
Provided herein, inter alia, are non-crosslinked polymers that possess thermoresponsive properties.
Abraham J. Domb, Jacob Berlin
Filed: 28 Jun 18
Utility
IL-6 Signaling and Breast Cancer
15 Apr 20
The disclosure provides, inter alia, methods of detecting IL-6 signaling activity in T cells in breast cancer patients, such as breast cancer patients in remission.
Peter P. LEE
Filed: 21 Oct 19
Utility
Farnesoid X receptor antagonists
6 Apr 20
Provided herein are Famesoid X receptor (FXR) antagonists having the structure of formula (I), and pharmaceutical compositions comprising the compound of formula (I) and a pharmaceutically acceptable excipient.
Barry Forman, Donna Yu
Filed: 19 Mar 18